Otonomy announces workforce reductions
Otonomy announced a set of immediate actions to preserve capital, extend its cash runway, and build shareholder value following the recent negative AVERTS-1 Phase 3 trial results for OTIVIDEX in Ménière’s disease, including a reduction of non-commercial workforce by one-third. September 13, 2017